| Literature DB >> 26239213 |
Zahra Zamani1, Samad Zare1, Rajabali Sadrkhanlou2, Abbas Ahmadi2, Elham Movahed1.
Abstract
BACKGROUND: Hyperprolactinemia is a common side effect of antipsychotic drugs that requires further investigation. The current study was designed to evaluate dose-dependent effect of chlorpromazine (CPZ) on hormonal changes and uterine horn histological structure in rats. Moreover, the mammary glands were analyzed to show hyperprolactinemia-induced histological changes.Entities:
Keywords: Hyperprolactinemia; Rats; Uterus
Mesh:
Substances:
Year: 2015 PMID: 26239213 PMCID: PMC4649858 DOI: 10.7508/ibj.2015.04.006
Source DB: PubMed Journal: Iran Biomed J ISSN: 1028-852X
Mean serum levels of prolactin, luteinizing hormone (LH), follicle-stimulating hormone (FSH), estrogen and progesterone in different groups
| Hormones | Control | 3 mg/kg | 10 mg/kg | 30 mg/kg |
|---|---|---|---|---|
| Prolactin (ng/ml) | 55.75 ± 3.06 | 109.25 ± 13.37 | 223.75 ± 26.35 | 249.50 ± 25.82 |
| LH (ng/ml) | 0.56 ±0.05 | 0.58 ±0.06 | 0.30 ±0.02 | 0.26 ± 0.02 |
| FSH | 3.17 ± 0.48 | 1.97± 0.44 | 1.35 ± 0.2 | 1.13 ± 0.06 |
| Estrogen (pg/ml) | 41.50 ± 2.62 | 29.00 ± 1.47 | 29.50± 2.59 | 24.00 ± 0.40 |
| Progestron (ng/ml) | 18.12 ± 2.55 | 22.75 ± 3.11 | 32.07 ±3.75 | 33.82± 3.71 |
indicate significant differences (P < 0.05) between data of CPZ-administrated groups with control group, 3 mg/kg, and 10 mg/kg, respectively. All data are presented as mean ± SD. Data indicate significant differences (P < 0.05) between CPZ groups (n = 8 for each group) and the control group (n = 8 for each group).
Histomorphometric data for uterine horns in different groups
|
|
|
|
|
|
|---|---|---|---|---|
| Uterine horn diameter | 1241.02 ± 102.97 | 1539.65 ± 21.98 | 1780.25 ± 107.02 | 2296.28 ± 119.59 |
| Endometrial epithelium height | 12.53 ± 2.50 | 20.06 ± 2.89 | 25.05 ± 4.09 | 42.60 ± 4.79 |
| Endometrial thickness | 265.67± 28.85 | 358.21± 11.69 | 368.37 ±28.41 | 426.50 ±29.90 |
| Myometrium thickness | 205.31 ± 43.12 | 287.32 ± 34.35 | 340.21 ± 42.25 | 517.25± 56.31 |
| Perimetrium thickness | 16.25 ± 2.89 | 26.50 ± 3.06 | 38.50 ± 5.60 | 41.56 ±4.79 |
indicate significant differences (P < 0.05) between data of CPZ-administrated groups with control group, 3 mg/kg, and 10 mg/kg, respectively. All data are presented as mean ± SD. CPZ administration increased uterine horn diameter by elevating endometrial, myometrium, and perimetrium thicknesses
Fig. 1Uterine horn cross-section. (A) control group, normal gland distribution in uterine horn; (B) High dose CPZ group (30 mg.kg). The gland distribution significantly increased per 1 mm2 of the endometrium in comparison to other groups (hematoxylin-eosin staining, magnification 400×). G, glands (arrows
Fig. 2Mean distribution of the glands per 1 mm2 of the uterine endometrium in different groups. CPZ administration increased gland number in endometrium. a,b indicate significant differences (P < 0.05) between data of CPZ-administrated groups with control group, 3 mg/kg, and 10 mg/kg, respectively. All data are presented as mean ± SD.
Fig. 3Mammary gland cross-section. Note inactive mammary glands in control (A). Developed secretory alveoli and ducts are presented in high dose (B) in CPZ-administrated groups. The lactating alveolus diameter in glands and the lactiferous duct distribution considerably was increased in CPZ-administrated animals (hematoxylin-eosin staining, magnific-ation 400×). Arrows indicate lactating alveolus
Histomorphometric data for mammary gland lobules in different group
| Parameters (μm) | Control | 3 mg/kg | 10 mg/kg | 30 mg/kg |
|---|---|---|---|---|
| Lobular diameter | 48.75 ± 4.43 | 84.12 ± 7.15 | 185.65 ± 54.80 | 254.03 ± 34.23 |
indicate significant differences (P < 0.05) between data of CPZ-administrated groups with control group, 3 mg/kg, and 10 mg/kg, respectively. All data are presented as mean ± SD. CPZ administration increased the lobular diameter in a dose-dependent manner.
Fig. 4Ovary cross-section. (A) Control group: the ovary from the control group is presented with different size follicles (F) and corpora lutea (CL); (B) The highest dose CPZ treatment group (30 mg/kg): the ovary from the treatment group in the highest dose of CPZ is presented with large and active CL without follicular growth (hematoxylin-eosin staining, magnification 400×)